Ascendis Pharma A/S Ordinary Share (ASND)

FairStock Score: 32/100 — RISKY

Key Financials

Strengths

• Generates $124 million in annual free cash flow (0.9% yield on market cap)
• Strong Piotroski F-Score of 7/9 indicating robust financial health across profitability, leverage, and efficiency metrics
• High return on equity of 332.6% demonstrating efficient capital deployment
• Altman Z-Score of 6.0 confirms minimal bankruptcy risk and strong solvency
• Revenue growth of 42.3% demonstrates strong top-line momentum

Concerns

• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration

AI Analysis

Ascendis Pharma A/S Ordinary Share is a mid-cap healthcare company valued at $14.1 billion. Revenue stands at $866 million, though the company is currently unprofitable. From a quality standpoint, Ascendis shows solid Piotroski F-Score of 7/9 and Altman Z-Score of 6.0 confirms fortress-level solvency. On valuation, the stock is trading at a premium 26.9x earnings, with PEG of 2.11 implies growth is already in the price. Growth dynamics show revenue growing at 42.3% and profit growth of 12.8%. Our composite FairStock Score of 32/100 reflects below-average fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.

Bull Case

Ascendis's 42% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $124 million in annual free cash flow (0.9% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer